Metabolic syndrome in patients with psoriatic disease

Abstract

Psoriasis is a common Th-1 and Th-17-mediated chronic inflammatory disease that has been associated with metabolic syndrome, a constellation of cardiovascular risk factors including obesity, hypertension, dyslipidemia, and insulin resistance. Overlapping inflammatory pathways and genetic susceptibility may be potential biologic links underlying this association. Multiple epidemiologic studies have consistently demonstrated higher prevalence of metabolic syndrome in patients with psoriasis. Dose-response relationships between more severe psoriasis and higher prevalence of metabolic syndrome components were recently established. This association has important clinical implications for the comprehensive management of psoriasis: Patients with psoriasis should be routinely screened for metabolic syndrome and treated accordingly to manage cardiometabolic risk, while clinicians should monitor potential effects on treatment efficacy and safety in patients with comorbid psoriasis and metabolic syndrome. Further research will be necessary to establish the directionality of this association and to explore the effect of treatment on these comorbid diseases.

Figure 1

Increasing psoriasis severity is associated with increasing odds of metabolic syndrome. OR, odds ratio; BSA, body surface area affected. Model adjusted for age and sex.

Figure 2

Increasing psoriasis severity is associated with increasing odds of metabolic syndrome components independent of other components. OR, odds ratio; BSA, body surface area affected. Model adjusted for age, sex, and other components of metabolic syndrome.